Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have recently been reported in many countries. These have exacerbated the coronavirus disease 2019 (COVID-19)-induced global health threats and hindered COVID-19 vaccine development and therapeutic progress. This commentar...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Md. Jamal Hossain, Ali A. Rabaan, Abbas Al Mutair, Saad Alhumaid, Talha Bin Emran, G Saikumar, Saikat Mitra, Kuldeep Dhama
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Taylor & Francis Group 2022-01-01
Rangatū:	Human Vaccines & Immunotherapeutics
Ngā marau:	sars-cov-2 b.1.621 sub-lineage b.1.621.1 mu variant vaccine breakthrough genomic surveillance global mass vaccination non-pharmaceutical interventions (npis)
Urunga tuihono:	http://dx.doi.org/10.1080/21645515.2022.2027197
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!